Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...

Researchers evaluated the efficacy and safety of the induction treatment with mycophenolate mofetil and cyclophosphamide for lupus nephritis. Mycophenolate mofetil (MMF) may be superior to ...

Nov. 1, 2002 — Mycophenolate (Mofetil) or azathioprine were found to be better than intravenous cyclophosphamide for maintenance of lupus nephritis, according to interim analysis of a long-term ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

London, UK - Mycophenolate mofetil (MMF) (CellCept, Roche Pharmaceuticals) allowed patients with lupus nephritis or treatment-resistant systemic lupus erythematosus (SLE) to significantly reduce their ...

WASHINGTON--(BUSINESS WIRE)-- The Lupus Foundation of America today praised the results of a new long-term study for the treatment of lupus nephritis (lupus-related kidney disease) which demonstrated ...

CHAPEL HILL, N.C. – A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for ...

Despite its flawed safety and efficacy, cyclophosphamide remains the standard therapy for severe lupus nephritis. Mycophenolate mofetil shows promise as an alternative. In addition to prednisone 1 ...

Mycophenolate mofetil (MMF) has mainly been used to treat lupus nephritis. Recent studies, however, have shown that MMF could be a safe and effective alternative therapy for patients with systemic ...

The evaluation committee considered evidence submitted by Roche, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...